Physician profile
Andrew N Garner
NPI 1821398678
$7,163.24
in general payments reported to CMS, 2019-2025
28 companies · $2,196 in 2025
The $2,196 reported for 2025 was more than what 95% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,202 · 2022: $1,082 · 2023: $1,773 · 2024: $910 · 2025: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,777 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,777.06 |
| Education | $101.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,663.26 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $845.94 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $736.96 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $723.47 | 2021-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $578.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $256.61 | 2021-2025 | Ocaliva |
| Ardelyx, INC. | $207.21 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $148.54 | 2021-2024 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $105.41 | 2021-2023 | |
| Pfizer INC. | $94.39 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $89.67 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $81.55 | 2024-2025 | Zenpep |
| Genzyme Corporation | $80.09 | 2023-2025 | |
| Amgen INC. | $80.04 | 2021-2023 | Avsola, Amjevita |
| Regeneron Healthcare Solutions, INC. | $67.52 | 2022-2023 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $48.94 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $47.41 | 2021 | |
| Celgene Corporation | $42.04 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $41.57 | 2021-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $40.69 | 2024 | Voquezna |
| Lilly USA, LLC | $35.60 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.26 | 2023 | Cyltezo |
| Ethicon US, LLC | $24.25 | 2021 | |
| Merck Sharp & Dohme LLC | $21.52 | 2023 | Dificid |
| Octapharma USA, INC. | $19.34 | 2024 | Balfaxar |
| Fresenius Kabi USA, LLC | $18.87 | 2023 | Idacio |
| Organon LLC | $16.42 | 2021 | |
| Bsn Medical INC | $14.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.